Hillstream Competitors

Delisted . USA . 
Stock . Hillstream Biopharma
Hillstream Biopharma competes with Virax Biolabs, Revelation Biosciences, Kiora Pharmaceuticals, ZyVersa Therapeutics, and Palisade Bio; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Hillstream Biopharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Hillstream Biopharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Hillstream Biopharma competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.000.000.00
Details
Intrinsic
Valuation
LowRealHigh
0.000.000.00
Details

Hillstream Biopharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Hillstream Biopharma and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Hillstream and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Hillstream Biopharma does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
PALI
+ 0.82
REVB
IMMX
+ 0.74
UNCY
ZVSA
+ 0.53
KPRX
REVB
+ 0.38
VRAX
PALI
+ 0.3
VRAX
ZVSA
+ 0.28
VRAX
  
High negative correlations   
UNCY
- 0.42
ZVSA
PALI
- 0.37
ZVSA
ZVSA
- 0.35
REVB
IMMX
- 0.28
ZVSA
PALI
- 0.27
KPRX
KPRX
- 0.24
REVB

Risk-Adjusted Indicators

There is a big difference between Hillstream Stock performing well and Hillstream Biopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Hillstream Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
VRAX  6.08  0.21  0.03  0.19  6.65 
(7.65)
 16.67 
(10.93)
 59.66 
BWV  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
REVB  6.48 (1.24) 0.00  1.45  0.00 
 0.00 
 17.05 
(15.43)
 71.84 
KPRX  3.07  0.15  0.03  0.20  3.98 
(3.14)
 7.44 
(5.87)
 21.16 
ZVSA  3.94  0.00  0.00 (0.01) 0.00 
 0.00 
 12.03 
(6.96)
 34.10 
PALI  5.34 (1.03) 0.00  3.10  0.00 
 0.00 
 3.95 
(11.84)
 93.57 
UNCY  4.20  0.37  0.07  0.33  4.38 
(5.15)
 9.43 
(7.50)
 28.72 
APGN  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
IMMX  3.98  0.09  0.02 (0.34) 4.52 
(4.96)
 9.09 
(7.69)
 33.17 
All Fundamental Data

Hillstream Biopharma Competitive Analysis

The better you understand Hillstream Biopharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Hillstream Biopharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Hillstream Biopharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
VRAX REVB KPRX ZVSA PALI UNCY IMMX QNRX CDIO
 2.31 
 1.69 
Virax
 5.01 
 3.60 
Revelation
 0.60 
 3.38 
Kiora
 8.20 
 1.12 
ZyVersa
 6.32 
 0.89 
Palisade
 5.56 
 0.57 
Unicycive
 0.61 
 1.64 
Immix
 3.13 
 0.31 
Quoin
 2.00 
 0.49 
Cardio
Market Volatility
(90 Days Market Risk)
Very risky
Very risky
Unstable
Extremely Dangerous
Out of control
Dangerous
Very risky
Out of control
Out of control
Market Performance
(90 Days Performance)
Weak
Very Weak
Insignificant
Insignificant
Very Weak
Very Weak
Very Weak
Very Weak
OK
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Very High
Low
Average
Very High
Low
Average
Average
Below Average
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Fairly Valued
Over Valued
Over Valued
Under Valued
Under Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Strong Sell
Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Buy
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Cautious Hold
Cautious Hold
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Cautious Hold
Current Ratio
0.04
0.68
1.53
N/A
2.59
4.43
19.53
0.96
18.42
Net Asset
5.48 M
12.21 M
13.71 M
22.11 M
14.05 M
14.19 M
19.93 M
12.17 M
4.46 M
Profit Margin
N/A
N/A
0.2
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(6.61 M)
(95.21 K)
(12.35 M)
(107.74 M)
(12.28 M)
(30.18 M)
(16.14 M)
(9.27 M)
(1.53 M)
Current Valuation
432.39 K
(4.56 M)
(18.88 M)
(169.36 K)
(5.09 M)
28.13 M
26.37 M
(7.78 M)
24.51 M
Price To Book
0.85
0.74
0.34
0.4
0.39
2.14
2.56
0.46
6.9
Operating Margin
-581.12
N/A
-121.23
N/A
N/A
N/A
N/A
N/A
-214.13
Retained Earnings
(18.53 M)
(25.47 M)
(146.98 M)
(103.22 M)
(121.51 M)
(64.54 M)
(53.41 M)
(46.2 M)
(14.37 M)
Five Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
One Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
1.61
0.19
-0.29
0.46
1.36
2.23
0.23
1.62
3.55
Number Of Employees
17
9
12
7
9
14
14
4
7
Shares Outstanding
4.34 M
522.28 K
2.97 M
2.51 M
2.77 M
103.8 M
27.51 M
8.19 M
52.15 M
Three Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash Flow From Operations
(6.25 M)
(7.29 M)
(9.56 M)
(8.72 M)
(11.13 M)
(18.28 M)
(11.37 M)
(7.86 M)
(5.67 M)
Total Debt
224.3 K
5.56 M
106.89 K
8.66 K
369 K
811 K
3.72 M
3.52 K
1.26 M
Return On Equity
-0.91
-2.7
0.14
-1.6
-1.36
-1.47
-1.18
-1.35
-2.76
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.48
-0.51
0.13
-0.23
-0.68
-0.63
-0.61
-0.44
-1.0
Number Of Shares Shorted
59.01 K
63.43 K
18.89 K
129.57 K
136.96 K
823.32 K
335.27 K
52.82 K
1.76 M
Book Value Per Share
1.99
9.97
7.14
6.54
5.51
0.28
0.64
1.08
0.12
Total Asset
5.48 M
12.21 M
13.71 M
22.11 M
14.05 M
14.19 M
19.93 M
12.17 M
4.46 M
Short Ratio
0.15
0.13
0.27
0.06
0.14
0.72
3.26
0.01
0.45
Target Price
20.0
170.73
30.33
20.0
30.33
5.5
7.0
4.5
2.0
Debt To Equity
N/A
0.009
0.018
N/A
0.23
0.023
0.002
0.47
N/A
Shares Owned By Institutions
6.72
11.8
48.34
3.23
7.2
60.39
12.15
18.89
4.9
Market Capitalization
7.51 M
1.98 M
10.75 M
2.96 M
2.59 M
59.67 M
45.11 M
2.52 M
25.77 M
Price To Earning
N/A
8.69
N/A
N/A
0.16
N/A
N/A
N/A
N/A
Price To Sales
88.5
2.88
0.63
N/A
14.03
62.82
N/A
N/A
722.1
Net Income
(6.74 M)
(120.25 K)
(12.51 M)
(98.3 M)
(12.3 M)
(30.54 M)
(15.6 M)
(8.69 M)
(8.38 M)
Earnings Per Share
-2.67
-266.71
16.53
519.07
-13.26
-0.48
-0.84
-3.66
-0.3
Shares Owned By Insiders
6.63
0.1
2.3
0.25
0.79
6.12
40.09
16.8
7.68
Revenue
156.42 K
N/A
N/A
N/A
250 K
675 K
N/A
N/A
17.07 K
Working Capital
4.21 M
6.58 M
3.1 M
(6.84 M)
10.74 M
(4.13 M)
16.07 M
7.7 M
1.92 M
Ten Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash And Equivalents
21.76 K
3.48 M
2.43 M
N/A
5 M
10.57 M
18.4 M
2.69 M
9.66 M
Cash Per Share
N/A
0.15
2.64
N/A
0.23
0.7
1.32
0.56
5.08
Gross Profit
33.6 K
90.91 M
(5.14 M)
N/A
N/A
N/A
N/A
N/A
35.69 K
Day Typical Price
1.69
3.55
3.38
1.11
0.91
0.56
1.66
0.31
0.5
Accumulation Distribution
0.0743
40867.54
318.78
0.0862
0.0928
17502.21
1476.51
N/A
74375.47
Market Facilitation Index
0.13
0.0
0.0
0.1
0.09
N/A
0.0
N/A
N/A
Daily Balance Of Power
(0.31)
(0.29)
0.2
(1.00)
(0.67)
1.0
0.1429
(9,223,372,036,855)
(0.20)
Period Momentum Indicator
(0.04)
(0.19)
0.02
(0.10)
(0.06)
0.03
0.01
(0.01)
(0.01)
Rate Of Daily Change
0.98
0.95
1.01
0.92
0.94
1.06
1.01
0.97
0.98
Day Median Price
1.69
3.52
3.38
1.11
0.93
0.55
1.67
0.31
0.51
Price Action Indicator
(0.01)
(0.01)
0.01
(0.04)
(0.07)
0.03
(0.02)
(0.01)
(0.02)
Relative Strength Index
46.81
38.56
47.39
47.53
30.75
50.13
42.44
40.36
47.18
Coefficient Of Variation
4197.46
(897.05)
2710.6
(1,698,221)
(1,046)
1462.34
5712.44
(1,169)
768.37
Mean Deviation
6.08
6.48
3.07
3.94
5.34
4.2
3.98
5.58
10.06
Jensen Alpha
0.2138
(1.24)
0.148
(0)
(1.03)
0.368
0.0875
(0.73)
1.89
Total Risk Alpha
0.2869
(1.14)
0.1797
0.0401
(0.94)
0.4087
0.139
(0.66)
2.01
Sortino Ratio
0.0307
N/A
0.0336
N/A
N/A
0.0719
0.0188
N/A
0.1902
Downside Variance
48.19
N/A
19.8
N/A
N/A
26.11
25.95
N/A
98.28
Standard Deviation
9.11
10.98
4.15
5.74
10.67
5.43
5.67
8.43
14.52
Kurtosis
5.67
7.55
0.3912
4.59
28.23
1.04
2.25
4.7
2.95
Potential Upside
16.67
17.05
7.44
12.03
3.95
9.43
9.09
14.29
38.46
Treynor Ratio
0.1947
1.45
0.1965
(0.01)
3.1
0.3349
(0.34)
1.67
1.18
Maximum Drawdown
59.66
71.84
21.16
34.1
93.57
28.72
33.17
58.63
77.44
Variance
82.92
120.54
17.25
32.95
113.94
29.44
32.1
71.05
210.73
Market Risk Adjusted Performance
0.2047
1.46
0.2065
(0)
3.11
0.3449
(0.33)
1.68
1.19
Risk Adjusted Performance
0.0267
(0.07)
0.0354
0.0087
(0.06)
0.059
0.0216
(0.05)
0.1053
Skewness
1.65
0.068
0.2585
1.66
4.12
0.6812
0.9254
0.6938
1.44
Semi Deviation
6.65
N/A
3.98
N/A
N/A
4.38
4.52
N/A
8.54
Information Ratio
0.0234
(0.11)
0.036
(0.0007)
(0.1)
0.0677
0.0169
(0.09)
0.1299
Value At Risk
(10.93)
(15.43)
(5.87)
(6.96)
(11.84)
(7.50)
(7.69)
(9.59)
(20.34)
Expected Short fall
(7.65)
N/A
(3.14)
N/A
N/A
(5.15)
(4.96)
N/A
(16.32)
Downside Deviation
6.94
N/A
4.45
N/A
N/A
5.11
5.09
N/A
9.91
Semi Variance
44.16
N/A
15.81
N/A
N/A
19.2
20.39
N/A
72.94

Hillstream Biopharma Competition Performance Charts

Five steps to successful analysis of Hillstream Biopharma Competition

Hillstream Biopharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Hillstream Biopharma in relation to its competition. Hillstream Biopharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Hillstream Biopharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Hillstream Biopharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Hillstream Biopharma, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Hillstream Biopharma position

In addition to having Hillstream Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Video Games Thematic Idea Now

Video Games
Video Games Theme
Companies that are involved in the building and marketing of video games or gaming software. The Video Games theme has 22 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Video Games Theme or any other thematic opportunities.
View All  Next Launch
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.

Other Consideration for investing in Hillstream Stock

If you are still planning to invest in Hillstream Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hillstream Biopharma's history and understand the potential risks before investing.
CEOs Directory
Screen CEOs from public companies around the world
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY